← All trials
NCT02087722
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2013
- Primary completion
- Jan 1, 2014
- Completion date
- Jan 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Kuhnil Pharmaceutical Co., Ltd.Lead sponsor
- Konkuk UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Neurim Pharmaceuticals Ltd.Collaborator
- Catholic University of KoreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.